• Home
  • Search Results
  • Monte Carlo investigation of I-125 interseed attenuation for standard and thinner seeds in prostate brachytherapy with phantom validation using a MOSFET.

Monte Carlo investigation of I-125 interseed attenuation for standard and thinner seeds in prostate brachytherapy with phantom validation using a MOSFET.

Medical physics (2013-03-08)
J Mason, B Al-Qaisieh, P Bownes, A Henry, D Thwaites
ABSTRACT

In permanent seed implant prostate brachytherapy the actual dose delivered to the patient may be less than that calculated by TG-43U1 due to interseed attenuation (ISA) and differences between prostate tissue composition and water. In this study the magnitude of the ISA effect is assessed in a phantom and in clinical prostate postimplant cases. Results are compared for seed models 6711 and 9011 with 0.8 and 0.5 mm diameters, respectively. A polymethyl methacrylate (PMMA) phantom was designed to perform ISA measurements in a simple eight-seed arrangement and at the center of an implant of 36 seeds. Monte Carlo (MC) simulation and experimental measurements using a MOSFET dosimeter were used to measure dose rate and the ISA effect. MC simulations of 15 CT-based postimplant prostate treatment plans were performed to compare the clinical impact of ISA on dose to prostate, urethra, rectum, and the volume enclosed by the 100% isodose, for 6711 and 9011 seed models. In the phantom, ISA reduced the dose rate at the MOSFET position by 8.6%-18.3% (6711) and 7.8%-16.7% (9011) depending on the measurement configuration. MOSFET measured dose rates agreed with MC simulation predictions within the MOSFET measurement uncertainty, which ranged from 5.5% to 7.2% depending on the measurement configuration (k = 1, for the mean of four measurements). For 15 clinical implants, the mean ISA effect for 6711 was to reduce prostate D90 by 4.2 Gy (3%), prostate V100 by 0.5 cc (1.4%), urethra D10 by 11.3 Gy (4.4%), rectal D2cc by 5.5 Gy (4.6%), and the 100% isodose volume by 2.3 cc. For the 9011 seed the mean ISA effect reduced prostate D90 by 2.2 Gy (1.6%), prostate V100 by 0.3 cc (0.7%), urethra D10 by 8.0 Gy (3.2%), rectal D2cc by 3.1 Gy (2.7%), and the 100% isodose volume by 1.2 cc. Differences between the MC simulation and TG-43U1 consensus data for the 6711 seed model had a similar impact, reducing mean prostate D90 by 6 Gy (4.2%) and V100 by 0.6 cc (1.8%). ISA causes the delivered dose in prostate seed implant brachytherapy to be lower than the dose calculated by TG-43U1. MC simulation of phantom seed arrangements show that dose at a point can be reduced by up to 18% and this has been validated using a MOSFET dosimeter. Clinical simulations show that ISA reduces DVH parameter values, but the reduction is less for thinner seeds.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Poly(methyl methacrylate), average Mw ~120,000 by GPC
Sigma-Aldrich
Poly(methyl methacrylate), average Mw ~350,000 by GPC
Sigma-Aldrich
Poly(methyl methacrylate), average Mw ~15,000 by GPC, powder
Sigma-Aldrich
Poly(methyl methacrylate)
Supelco
Poly(methyl methacrylate), analytical standard, for GPC, 2,000
Sigma-Aldrich
Poly(methyl methacrylate), isotactic, >80% isotactic
Supelco
Poly(methyl methacrylate), analytical standard, for GPC, 2,480,000
Supelco
Poly(methyl methacrylate), analytical standard, for GPC, 100,000
Supelco
Poly(methyl methacrylate), analytical standard, for GPC, average Mw 97,000 (Typical), average Mn 46,000 (Typical)
Supelco
Poly(methyl methacrylate), analytical standard, for GPC, 20,000
Supelco
Poly(methyl methacrylate), analytical standard, for GPC, 50,000
Supelco
Poly(methyl methacrylate), analytical standard, for GPC, 10,000
Supelco
Poly(methyl methacrylate), analytical standard, for GPC, 4,000
Supelco
Poly(methyl methacrylate), analytical standard, for GPC, 8,000